ConductScience.org, home

Paper41423596

Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing.

Devine B and 12 others. BMC Prim Care, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing. Papers, record 41423596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41423596

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cost-effectiveness of primary care-based risk assessment and hereditary cancer genetic testing.
PubMed
Journal
BMC Prim Care
PubMed
Year
2025
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-07-02
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Devine BBeth
2Aalbers SESanne E
3Chan HHuiHsuan
4Jiang SShangqing
5Dusic EJEmerson J
6Knerr SSarah
7Harris HMHeather M
8Wang CCatharine
9Norquist BMBarbara M
10Riemann LALaurie A
11Brant JMJeannine M
12Shirts BHBrian H
13Swisher EMElizabeth M

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Genetic TestingMajor topic
Primary Health CareMajor topic
Early Detection of CancerMajor topic
NeoplasmsMajor topic
Humans
Cost-Benefit Analysis
Cost-Effectiveness Analysis
Risk Assessment
Female
Male
Middle Aged
Quality-Adjusted Life Years

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U01 CA232795NCI NIH HHSUnited StatesU01CA232795PubMed and NIHNIH RePORTER
U01CA232795National Cancer Institute, NIHU01CA232795PubMed and NIHNIH RePORTER
UL1-TR002319NIH National Institute of Health & NCI National Cancer InstituteUL1TR002319PubMedNIH RePORTER
KL2-TR002317NIH National Institutes of Health & NCI National Cancer InstituteKL2TR002317PubMedNIH RePORTER
TL1-TR002318NIH National Institutes of Health & (NCATS) National Center for Advancing Translation SciencesTL1TR002318PubMedNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04746794Early Detection of GEnetic Risk (EDGE)Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125698379Practical opportunities to improve early detection and prevention of colorectal cancer (CRC) in members of high-risk families.Dig Dis Sci2015https://conductscience.org/library/papers/25698379PubMed
232601386Clinical outcomes of a genomic screening program for actionable genetic conditions.Genet Med2020https://conductscience.org/library/papers/32601386PubMed
336386046Barriers, interventions, and recommendations: Improving the genetic testing landscape.Front Digit Health2022https://conductscience.org/library/papers/36386046PubMed
437856201NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.J Natl Compr Canc Netw2023https://conductscience.org/library/papers/37856201PubMed
533119106Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.JAMA Netw Open2020https://conductscience.org/library/papers/33119106PubMed
622446623A self-administered family history questionnaire improves identification of women who warrant referral to genetic counseling for hereditary cancer risk.Gynecol Oncol2012https://conductscience.org/library/papers/22446623PubMed
738353949Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.JAMA Netw Open2024https://conductscience.org/library/papers/38353949PubMed
837435610Payer reimbursement practices and incentives for improving interpretation of germline genetic testing.J Law Biosci2023https://conductscience.org/library/papers/37435610PubMed
931388181Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries.Nat Med2019https://conductscience.org/library/papers/31388181PubMed
1040233717Precision oncology and genetic ancestry: The science behind population-based cancer disparities.Cancer Cell2025https://conductscience.org/library/papers/40233717PubMed
1133373667Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care.Contemp Clin Trials2021https://conductscience.org/library/papers/33373667PubMed
1221350618CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials.J Pharmacol Pharmacother2010https://conductscience.org/library/papers/21350618PubMed
1332642924Knowledge, Attitudes, Willingness to Pay, and Patient Preferences About Genetic Testing and Subsequent Risk Management for Cancer Prevention.J Cancer Educ2022https://conductscience.org/library/papers/32642924PubMed
1429998407Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.Ann Surg Oncol2018https://conductscience.org/library/papers/29998407PubMed
1540053353Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics: A Cluster Randomized Clinical Trial.JAMA Netw Open2025https://conductscience.org/library/papers/40053353PubMed
1635144679Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.Hered Cancer Clin Pract2022https://conductscience.org/library/papers/35144679PubMed
1734638366Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34638366PubMed
1824567435Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.J Clin Oncol2014https://conductscience.org/library/papers/24567435PubMed
1928632866Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.JAMA2017https://conductscience.org/library/papers/28632866PubMed
2038421676MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.JAMA Oncol2024https://conductscience.org/library/papers/38421676PubMed

See all 27 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41423596

GET https://conductscience.org/api/papers/v1/41423596/references?page=2